The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study

• DOI: 10.2967/jnumed.111.093864
• Publication Date: 2011-08-31T00:57:03Z
• Authors: David Groheux; Sylvie Giacchetti; Marc Espié; Laetitia Vercellino; Anne-Sophie Hamy; Marc Delord; Nathalie Berenger; Marie-Elisabeth T...; Jean-Louis Misset; Elif Hindié
• Keywords: Fluorine Radioisotopes; Bone Neoplasms; Breast Neoplasms; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Fluorodeoxyglucose F18; Lymphatic Metastasis; Positron-Emission Tomography; Humans; Female; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed; Neoplasm Staging

The purpose of this study was to prospectively evaluate the role ¹⁸F-FDG PET/CT in patients with stage IIA, IIB, or IIIA breast cancer. <b>Methods:</b> During 56 mo, 131 consecutive large (&gt;2 cm) cancer and clinical (based on examination, mammography, MRI, ultrasonography) underwent PET/CT. nuclear physician unaware results any other procedure (bone scan, chest radiography, liver ultrasound, thoracoabdominal CT scan). <b>Results:</b> Of examined patients, 36 had IIA (34 T2N0 2 T1N1), 48 IIB (20 T3N0 28 T2N1), 47 (29 T3N1, 9 T2N2, T3N2). modified staging for 5.6% 14.6% 27.6% patients. However, within IIIA, yield specifically high among 18 N2 disease (56% modification). When considering primary operable (T3N1) together, 13% (10/77); extraaxillary regional lymph nodes were detected 5 distant metastases 7 In series, outperformed bone scanning, only 1 misclassification versus 8 scanning (<i>P</i> = 0.036). <b>Conclusion:</b>¹⁸F-FDG provided useful information T3N0, T2N1, T3N1 disease. more modest IIA. case demonstrates that comprises quite distinct groups